Progesterone Vaginal — Membership Pricing

Other medications in Women's Health

• Relugolix
• Terbutaline
• Betamethasone Prenatal
• Carboprost
• Clomiphene Citrate
• Danazol
• Desogestrel-Ethinyl Estradiol
• Dienogest

About Progesterone Vaginal

Progesterone vaginal is a crucial medication often prescribed to support various aspects of women's reproductive health, from fertility treatments to hormone replacement. Understanding its role and how to access it affordably is key. At TheDrugClub, we're dedicated to helping you manage your prescription costs, including for essential medications like progesterone vaginal, ensuring you get the care you need without breaking the bank.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Progesterone Vaginal is approved for (FDA label)

ENDOMETRIN ® is indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks. ENDOMETRIN is a progesterone indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks.

Source: Read the full FDA label on DailyMed. Label effective date: July 29, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Progesterone Vaginal (FDA label)

Vaginal insert: 100 mg - white to off-white oblong-shaped debossed with “FPI” on one side and “100” on the other side. Vaginal insert: 100 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 2ba50fa9-b349-40cb-9a4b-1af8faa4ec09. SPL document ID: 7ff9c412-250d-4db8-b425-51c200241848. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Progesterone Vaginal (FDA label)

The most common adverse reactions reported (greater than 2%) were post-oocyte retrieval pain, abdominal pain, nausea, and ovarian hyperstimulation syndrome. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc. at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 2ba50fa9-b349-40cb-9a4b-1af8faa4ec09. SPL document ID: 7ff9c412-250d-4db8-b425-51c200241848. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Progesterone Vaginal (FDA label)

ENDOMETRIN is contraindicated in women with any of the following conditions: Previous hypersensitivity reactions to progesterone or any of the ingredients of ENDOMETRIN [ see Description ( 11 ) ] Abnormal vaginal bleeding that has an undiagnosed etiology Known missed abortion or ectopic pregnancy Hepatic adenoma, hepatocellular carcinoma, acute hepatitis, or severe (decompensated) cirrhosis Current diagnosis of, or history of, a hormone-sensitive malignancy (e.g., breast cancer) Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events ENDOMETRIN is contraindicated in patients with ( 4 ): Previous hypersensitivity reactions to progesterone or any of the ingredients in ENDOMETRIN Abnormal vaginal bleeding that has an undiagnosed etiology Known missed abortion or ectopic pregnancy Hepatic adenoma, hepatocellular carcinoma, acute hepatitis, or severe (decompensated) cirrhosis Current diagnosis of, or history of, a hormone-sensitive malignancy (e.g., breast cancer) Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events

Source: FDA prescribing information (DailyMed). Set ID: 2ba50fa9-b349-40cb-9a4b-1af8faa4ec09. SPL document ID: 7ff9c412-250d-4db8-b425-51c200241848. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Progesterone Vaginal (FDA label)

Cardiovascular or Cerebrovascular Disorders: Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with ENDOMETRIN. Discontinue ENDOMETRIN if any of these are suspected. ( 5.1 ) Depression: Closely observe ENDOMETRIN-treated women with a history of depression. Consider ENDOMETRIN discontinuation if symptoms worsen. (5.2) 5.1 Cardiovascular or Cerebrovascular Disorders Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with ENDOMETRIN. The healthcare provider should be alert to earliest signs of myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis. ENDOMETRIN should be discontinued if any of these are suspected. 5.2 Depression ENDOMETRIN-treated women with a history of depression should be closely observed. Consider ENDOMETRIN discontinuation if symptoms worsen.

Source: FDA prescribing information (DailyMed). Set ID: 2ba50fa9-b349-40cb-9a4b-1af8faa4ec09. SPL document ID: 7ff9c412-250d-4db8-b425-51c200241848. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Progesterone Vaginal (FDA label)

Drugs known to induce the hepatic cytochrome-P450-3A4 system may increase the elimination of progesterone, lower progesterone exposure in ENDOMETRIN-treated women, and reduce the efficacy of ENDOMETRIN. The effect of concomitant vaginal products on the exposure of progesterone from ENDOMETRIN has not been assessed. ENDOMETRIN is not recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the ENDOMETRIN vaginal insert. CYP3A4 Inducers: May increase the elimination of progesterone and may reduce the efficacy of ENDOMETRIN. ( 7 ) Other Vaginal Products: Avoid use of ENDOMETRIN with other vaginal products. ( 7 )

Source: FDA prescribing information (DailyMed). Set ID: 2ba50fa9-b349-40cb-9a4b-1af8faa4ec09. SPL document ID: 7ff9c412-250d-4db8-b425-51c200241848. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.